相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
Stefano Fogli et al.
CANCER TREATMENT REVIEWS (2020)
Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis
Chenglong Chen et al.
CLINICAL GENITOURINARY CANCER (2019)
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
Gregory T. Sneed et al.
CLINICAL GENITOURINARY CANCER (2019)
Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options
Andrew Schmidt et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature
Marco Bandini et al.
CLINICAL GENITOURINARY CANCER (2018)
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Nizar M. Tannir et al.
ONCOLOGIST (2018)
Risk factors for locoregional relapse after radical nephrectomy
Sameer Jhavar et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Kidney Cancer, Version 2.2017 Clinical Practice Guidelines in Oncology
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review
Alessandro Leonetti et al.
CLINICAL GENITOURINARY CANCER (2016)
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Mohmad Hussain Mir et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2016)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group
Ali Tafreshi et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
William K. Oh et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor
F. J. Afonso et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma
Hideaki Miyake et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
Ezzeldin M. Ibrahim et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
N. Calvani et al.
MEDICAL ONCOLOGY (2012)
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
Loukas Kontovinis et al.
MEDICAL ONCOLOGY (2012)
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
Joaquim Bellmunt et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
Arkadiusz Z. Dudek et al.
CANCER (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
Giuseppe Di Lorenzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence
Scott E. Eggener et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
